Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Authors:
- 25 February 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (4) , 525-533
Abstract
Identification of tumor genomic alterations predictive of therapeutic benefit from targeted therapy has improved clinical outcomes across a wide range of malignant neoplasms.1-7 Examples include EGFR-mutant non–small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors, ERBB2 (formerly HER2/neu)-amplified breast cancer treated with human epidermal growth factor receptor 2–specific antibodies, and tumors with microsatellite instability treated with immune checkpoint blockade. Because identification of these targets susceptible to drug therapy has improved clinical outcomes, interest in using next-generation sequencing (NGS) testing for advanced solid tumors to identify patients who qualify for enrollment in biomarker-selected clinical trials is increasing. Next-generation sequencing testing can be obtained via commercial or institutional platforms, and these differ significantly in their scope; some are limited to DNA-based testing of a select group of known, targetable cancer-related genes. Others use unbiased, comprehensive DNA- and RNA-based analyses of samples consisting of tumor and normal samples, with additional goals of identifying novel somatic alterations or pathogenic germline variants (PGVs) conferring increased cancer risk.Keywords
This publication has 35 references indexed in Scilit:
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical TrialsJournal of Clinical Oncology, 2015
- On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 PatientsMolecular Cancer Therapeutics, 2015
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark AnalysesClinical Cancer Research, 2014
- Molecular Analysis for Therapy Choice: NCI MATCHSeminars in Oncology, 2014
- Modeling tissue contamination to improve molecular identification of the primary tumor site of metastasesBioinformatics, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Trastuzumab containing regimens for early breast cancerCochrane Database of Systematic Reviews, 2012
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot StudyScience Translational Medicine, 2011
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001